Anna F. Offersgaard
Copenhagen, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspots.
Journal: Emerging microbes & infections
Published: October 15, 2025
Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 07, 2025
Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infection.
Journal: EBioMedicine
Published: June 10, 2024
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animals.
Journal: Scientific reports
Published: April 16, 2024
Toward a vaccine against hepatitis C virus.
Journal: Science (New York, N.Y.)
Published: April 06, 2023
Effect of Glycan Shift on Antibodies against Hepatitis C Virus E2 412-425 Epitope Elicited by Chimeric sHBsAg-Based Virus-Like Particles.
Journal: Microbiology spectrum
Published: January 31, 2023
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
Journal: Science advances
Published: December 21, 2022
Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotide.
Journal: Nature
Published: November 09, 2022
Identification of novel neutralizing determinants for protection against HCV.
Journal: Hepatology (Baltimore, Md.)
Published: May 06, 2022
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals.
Journal: iScience
Published: April 21, 2022
Last Updated: 09/26/2026